866-997-4948(US-Canada Toll Free)

United States Checkpoint Inhibitors for Treating Cancer Market Report 2017

Published By :

QYResearch

Published Date : Apr 2017

Category :

Cancer

No. of Pages : 102 Pages

In this report, the United States Checkpoint Inhibitors for Treating Cancer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Checkpoint Inhibitors for Treating Cancer in these regions, from 2012 to 2022 (forecast).

United States Checkpoint Inhibitors for Treating Cancer market competition by top manufacturers/players, with Checkpoint Inhibitors for Treating Cancer sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Bristol-Myers Squibb(BMS)
Merck
Roche
...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Checkpoint Inhibitors for Treating Cancer for each application, including
Melanoma Treatment
Bladder Cancer Treatment
Other

Table of Contents

United States Checkpoint Inhibitors for Treating Cancer Market Report 2017
1 Checkpoint Inhibitors for Treating Cancer Overview
1.1 Product Overview and Scope of Checkpoint Inhibitors for Treating Cancer
1.2 Classification of Checkpoint Inhibitors for Treating Cancer by Product Category
1.2.1 United States Checkpoint Inhibitors for Treating Cancer Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Checkpoint Inhibitors for Treating Cancer Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 PD-1 Inhibitors
1.2.4 PD-L1 Inhibitors
1.2.5 CTLA-4 Inhibitors
1.3 United States Checkpoint Inhibitors for Treating Cancer Market by Application/End Users
1.3.1 United States Checkpoint Inhibitors for Treating Cancer Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 United States Checkpoint Inhibitors for Treating Cancer Market by Region
1.4.1 United States Checkpoint Inhibitors for Treating Cancer Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)
1.4.3 Southwest Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)
1.4.5 New England Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)
1.4.6 The South Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)
1.4.7 The Midwest Checkpoint Inhibitors for Treating Cancer Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Checkpoint Inhibitors for Treating Cancer (2012-2022)
1.5.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2022)
1.5.2 United States Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2022)

2 United States Checkpoint Inhibitors for Treating Cancer Market Competition by Players/Suppliers
2.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Checkpoint Inhibitors for Treating Cancer Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Checkpoint Inhibitors for Treating Cancer Average Price by Players/Suppliers (2012-2017)
2.4 United States Checkpoint Inhibitors for Treating Cancer Market Competitive Situation and Trends
2.4.1 United States Checkpoint Inhibitors for Treating Cancer Market Concentration Rate
2.4.2 United States Checkpoint Inhibitors for Treating Cancer Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Sales Area, Product Type

3 United States Checkpoint Inhibitors for Treating Cancer Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Region (2012-2017)
3.2 United States Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Region (2012-2017)
3.3 United States Checkpoint Inhibitors for Treating Cancer Price by Region (2012-2017)

4 United States Checkpoint Inhibitors for Treating Cancer Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2012-2017)
4.3 United States Checkpoint Inhibitors for Treating Cancer Price by Type (2012-2017)
4.4 United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Type (2012-2017)

5 United States Checkpoint Inhibitors for Treating Cancer Sales (Volume) by Application (2012-2017)
5.1 United States Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Application (2012-2017)
5.2 United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 United States Checkpoint Inhibitors for Treating Cancer Players/Suppliers Profiles and Sales Data
6.1 Bristol-Myers Squibb(BMS)
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Checkpoint Inhibitors for Treating Cancer Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Merck
6.2.2 Checkpoint Inhibitors for Treating Cancer Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Roche
6.3.2 Checkpoint Inhibitors for Treating Cancer Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
...

7 Checkpoint Inhibitors for Treating Cancer Manufacturing Cost Analysis
7.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Checkpoint Inhibitors for Treating Cancer Major Manufacturers in 2016
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Checkpoint Inhibitors for Treating Cancer Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Checkpoint Inhibitors for Treating Cancer Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Checkpoint Inhibitors for Treating Cancer Sales Volume Forecast by Type (2017-2022)
11.3 United States Checkpoint Inhibitors for Treating Cancer Sales Volume Forecast by Application (2017-2022)
11.4 United States Checkpoint Inhibitors for Treating Cancer Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer


List of Table

List of Tables and Figures

Figure Product Picture of Checkpoint Inhibitors for Treating Cancer
Figure United States Checkpoint Inhibitors for Treating Cancer Market Size (K Pcs) by Type (2012-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume Market Share by Type (Product Category) in 2016
Figure PD-1 Inhibitors Product Picture
Figure PD-L1 Inhibitors Product Picture
Figure CTLA-4 Inhibitors Product Picture
Figure United States Checkpoint Inhibitors for Treating Cancer Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Application in 2016
Figure Melanoma Treatment Examples
Figure Bladder Cancer Treatment Examples
Figure Other Examples
Figure United States Checkpoint Inhibitors for Treating Cancer Market Size (Million USD) by Region (2012-2022)
Figure The West Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Checkpoint Inhibitors for Treating Cancer Sales Share by Players/Suppliers
Figure 2017 United States Checkpoint Inhibitors for Treating Cancer Sales Share by Players/Suppliers
Figure United States Checkpoint Inhibitors for Treating Cancer Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Players/Suppliers
Figure 2017 United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Players/Suppliers
Table United States Market Checkpoint Inhibitors for Treating Cancer Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Checkpoint Inhibitors for Treating Cancer Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Checkpoint Inhibitors for Treating Cancer Market Share of Top 3 Players/Suppliers
Figure United States Checkpoint Inhibitors for Treating Cancer Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Checkpoint Inhibitors for Treating Cancer Product Category
Table United States Checkpoint Inhibitors for Treating Cancer Sales (K Pcs) by Region (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Sales Share by Region (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Share by Region (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2016
Table United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Region (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2016
Table United States Checkpoint Inhibitors for Treating Cancer Price (USD/Pcs) by Region (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Sales (K Pcs) by Type (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2016
Table United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Checkpoint Inhibitors for Treating Cancer by Type (2012-2017)
Figure Revenue Market Share of Checkpoint Inhibitors for Treating Cancer by Type in 2016
Table United States Checkpoint Inhibitors for Treating Cancer Price (USD/Pcs) by Types (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Type (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Sales (K Pcs) by Application (2012-2017)
Table United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2016
Table United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Application (2012-2017)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Growth Rate by Application (2012-2017)
Table Bristol-Myers Squibb(BMS) Basic Information List
Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Revenue Market Share in United States (2012-2017)
Table Merck Basic Information List
Table Merck Checkpoint Inhibitors for Treating Cancer Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Merck Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2012-2017)
Figure Merck Checkpoint Inhibitors for Treating Cancer Sales Market Share in United States (2012-2017)
Figure Merck Checkpoint Inhibitors for Treating Cancer Revenue Market Share in United States (2012-2017)
Table Roche Basic Information List
Table Roche Checkpoint Inhibitors for Treating Cancer Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Roche Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2012-2017)
Figure Roche Checkpoint Inhibitors for Treating Cancer Sales Market Share in United States (2012-2017)
Figure Roche Checkpoint Inhibitors for Treating Cancer Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Checkpoint Inhibitors for Treating Cancer
Figure Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer
Figure Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis
Table Raw Materials Sources of Checkpoint Inhibitors for Treating Cancer Major Players/Suppliers in 2016
Table Major Buyers of Checkpoint Inhibitors for Treating Cancer
Table Distributors/Traders List
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Checkpoint Inhibitors for Treating Cancer Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Checkpoint Inhibitors for Treating Cancer Sales Volume Share Forecast by Region (2017-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume Share Forecast by Region (2017-2022)
Figure United States Checkpoint Inhibitors for Treating Cancer Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *